Document Detail


Human papillomavirus vaccines: current status and future prospects.
MedLine Citation:
PMID:  20518577     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Worldwide, cervical cancer is the second most common cancer of women. Less-developed countries bear the greatest burden in terms of morbidity and mortality, largely due to the lack of organized screening programmes. Cervical cancer is the first cancer shown to be caused solely by virological agents: oncogenic genotypes of human papillomavirus (HPV). Two recently developed prophylactic cervical cancer vaccines, which are based on viral-like particle (VLP) technology of HPV, have the capacity to diminish a large proportion of cervical cancer cases worldwide. However, to be successful public health tools, they need to be widely implemented to the appropriate target population, preferably prior to first sexual intercourse. To increase vaccination coverage, national programmes in some countries have also included catch-up vaccination, for a limited time period, to young adult women aged up to 26 years. Despite the excellent efficacy for high-grade dysplasia due to vaccine-related HPV types (near to 100%) and immunogenicity induced against the HPV types 16 and 18 in females naive to those HPV types pre-vaccination, some form of cervical precancer screening will still be necessary. Immunity to HPV is primarily type specific, and thus protection induced by the current generation of vaccines, based on a limited number of HPV VLP types, cannot provide complete protection against all oncogenic HPV types. Both these vaccines translate to protection of cervical cancer in the order of 70-75%, which represents the percentage of invasive cancers attributable to HPV-16 and -18. Challenges to ensuring the successful control of this largely preventable disease include endorsement by governments and policy makers, affordable prices, education at all levels, overcoming barriers to vaccination and continued adherence to screening programmes.
Authors:
Suzanne M Garland; Jennifer S Smith
Related Documents :
4339427 - Yellow fever vaccination, avian leukosis virus, and cancer risk in man.
14746037 - Vaccines against human papillomavirus and perspectives for the prevention and control o...
18930097 - Hpv antibody levels and clinical efficacy following administration of a prophylactic qu...
19366497 - Cost-effectiveness of human papillomavirus vaccination in belgium: do not forget about ...
8763977 - The influence of the hla-drb1*13 allele on measles vaccine response.
17258937 - An update on the search for a plasmodium vivax vaccine.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs     Volume:  70     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-06-03     Completed Date:  2010-08-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  1079-98     Citation Subset:  IM    
Affiliation:
Department of Microbiology and Infectious Diseases, Royal Women's Hospital, Melbourne, Victoria, Australia. suzanne.garland@thewomens.org.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Clinical Trials as Topic
Enzyme-Linked Immunosorbent Assay / methods
Female
Human papillomavirus 16 / immunology,  pathogenicity
Human papillomavirus 18 / immunology,  pathogenicity
Humans
Mass Vaccination
Papillomavirus Infections / immunology,  prevention & control*
Papillomavirus Vaccines* / administration & dosage,  adverse effects,  immunology
Risk Factors
Sexual Behavior
Sexually Transmitted Diseases, Viral / epidemiology,  prevention & control*
Uterine Cervical Diseases / immunology,  prevention & control*,  virology
Uterine Cervical Neoplasms / etiology*,  prevention & control
Young Adult
Chemical
Reg. No./Substance:
0/Papillomavirus Vaccines

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  On the [3 + 2] annulation of cyclic allylsilanes with N-phenyltriazolinedione: an enantio- and diast...
Next Document:  Novel aspects of pharmacological therapies for acute renal failure.